1-(2,4-dihydroxy-3-methylphenyl)-3-methylbutan-1-one | 664376-65-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2,4-dihydroxy-3-methylphenyl)-3-methylbutan-1-one
• 英文别名: 1-Butanone, 1-(2,4-dihydroxy-3-methylphenyl)-3-methyl-
• CAS: 664376-65-2
• 化学式: C₁₂H₁₆O₃
• 分子量: 208.257
• InChiKey: JWCPRUWAQRSCET-UHFFFAOYSA-N

物化性质

• 沸点：
  364.9±12.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2,4-dihydroxy-3-methylphenyl)-3-methylbutan-1-one 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 40.0 ℃ 、101.33 kPa 条件下， 反应 8.0h， 生成 methyl-3-(2-hydroxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-phenyl)propanoate
  参考文献：
  名称：

  3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2)

  摘要：

  We have identified and synthesized a brain penetrant propanoic acid as an allosteric potentiator of the metabotropic glutamate receptor 2. Structure-activity relationship studies directed toward improving the potency, level of potentiation and brain penetration led to the discovery of 8 (EC50 = 1200 nM, 77% potentiation, 119% brain/plasma in rat, 20 mpk ip, brain level of 5700 nM). © 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.078
• 作为产物：
  描述：

  异戊酸 在 aluminum (III) chloride 、 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 1-(2,4-dihydroxy-3-methylphenyl)-3-methylbutan-1-one
  参考文献：
  名称：

  Design and Synthesis of Systemically Active Metabotropic Glutamate Subtype-2 and -3 (mGlu_2/3) Receptor Positive Allosteric Modulators (PAMs): Pharmacological Characterization and Assessment in a Rat Model of Cocaine Dependence

  摘要：

  As part of our ongoing small-molecule metabotropic glutamate (mGlu) receptor positive allosteric modulator (PAM) research, we performed structure activity relationship (SAR) studies around a series of group II mGlu PAMs. Initial analogues exhibited weak activity as mGlu(2) receptor PAMs and no activity at mGlu(3). Compound optimization led to the identification of potent mGlu(2/3) selective PAMs with no in vitro activity at mGlu(1,4-8) or 45 other CNS receptors. In vitro pharmacological characterization of representative compound 44 indicated agonist-PAM activity toward mGlu(2) and PAM activity at mGlu(3). The most potent mGlu(2/3) PAMs were characterized in assays predictive of ADME/T and pharmacokinetic (PK) properties, allowing the discovery of systemically active mGlu(2/3) PAMs. On the basis of its overall profile, compound 74 was selected for behavioral studies and was shown to dose-dependently decrease cocaine self-administration in rats after intraperitoneal administration. These mGlu(2/3) receptor PAMs have significant potential as small molecule tools for investigating group II mGlu pharmacology.

  DOI：

  10.1021/jm5000563

文献信息

• ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME
  申请人：NISSAN CHEMICAL CORPORATION

  公开号：US20200165194A1

  公开（公告）日：2020-05-28

  The present invention provides a medium additive composition containing a compound represented by the following formula (I), or a salt thereof: wherein each symbol is as defined in the DESCRIPTION.}

  本发明提供一种含有由以下式（I）所表示的化合物或其盐的介质添加剂组合物： 其中每个符号如描述中所定义。}
• Acetophenone potentiators of metabotropic glutamate receptors
  申请人：Cube V. Rowena

  公开号：US20050288346A1

  公开（公告）日：2005-12-29

  The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及激活型代谢型谷氨酸受体的化合物，包括mGluR2受体，适用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型谷氨酸受体的疾病。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗涉及代谢型谷氨酸受体的疾病。
• Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors
  申请人：Pinkerton Anthony B

  公开号：US20080293684A1

  公开（公告）日：2008-11-27

  The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及化合物，它们是代谢型谷氨酸受体的增强剂，包括mGluR2受体，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病方面的使用。
• KINASE INHIBITOR
  申请人：Nissan Chemical Corporation

  公开号：EP3804707A1

  公开（公告）日：2021-04-14

  The present invention aims to provide a novel kinase inhibitor and the like, and a therapeutic agent for a disease, a drug discovery screening method and the like utilizing such inhibitor and the like. The compound represented by the following formula (I) and a salt thereof can inhibit plural kinases including LATS (particularly LATS2) which is the major kinase in the Hippo signal transduction pathway. In addition, diseases or tissue damage associated with failure of cellular proliferation can be treated. Therefore, the present invention is beneficial, for example, in the research field of cell functions and diseases, in which the Hippo signal transduction pathway is involved, and the like. Furthermore, it is beneficial in the medical field for the treatment of such diseases and the like. wherein each symbol is as defined in the DESCRIPTION.

  本发明旨在提供一种新型激酶抑制剂等，以及利用这种抑制剂等的疾病治疗剂、药物发现筛选方法等。下式（I）所代表的化合物及其盐可以抑制多种激酶，包括 LATS（尤其是 LATS2），它是 Hippo 信号转导通路中的主要激酶。此外，还可以治疗与细胞增殖失败有关的疾病或组织损伤。因此，本发明有利于细胞功能和疾病（其中涉及 Hippo 信号转导通路）等研究领域。此外，本发明还有利于医疗领域对此类疾病等的治疗。 其中各符号如说明书中所定义。
• Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: Identification and synthesis of phenyl-tetrazolyl acetophenones
  作者：Anthony B. Pinkerton、Rowena V. Cube、John H. Hutchinson、Blake A. Rowe、Hervé Schaffhauser、Xiumin Zhao、Lorrie P. Daggett、Jean-Michel Vernier

  DOI：10.1016/j.bmcl.2004.08.020

  日期：2004.11

  We have identified and synthesized a series of aryl-tetrazoyl acetophenones as positive allosteric potentiators of the metabotropic glutamate receptor 2. Structure activity relationship studies directed toward improving the potency and level of potentiation led to the discovery of 22 (EC50 = 93 nM, 128% potentiation). (C) 2004 Elsevier Ltd. All rights reserved.